Abstract
Despite the main complications of SARS-CoV-2 infection regard lung involvement, the prevalence of current smoking in COVID-19 patients is very low even if one might have anticipated that opposite. Thus, the epidemiological data seem to question the role of coexisting active smoking as a risk factor for COVID-19 pneumonia.
To the Editor
We have read with interest the paper by Leung et al. recently published in European Respiratory Journal [1], reporting a higher expression of the protein ACE-2 in the small airways epithelia of smokers and COPD patients with putatively important implications for COVID-19 patients since ACE-2 has been shown to be the receptor utilised by SARS-CoV-2 to enter the host cells [2]. Furthermore the Authors reported that current smokers showed a higher expression of ACE-2 gene expression than non-smokers, concluding that the increased ACE-2 expression in smokers might predispose to increased risk of SARS-CoV-2 infection [1].
To this regard, all epidemiological data published so far, reported that COVID-19 patients show a very low prevalence of smokers, with no significant association between current smoking and severe disease in COVID-19 patients [3–6].
At the University-Hospital of Padova, located in the Veneto Region, one of the most SARS-CoV-2 affected area in Italy, between March 15 and April 10 2020, 132 patients were assessed in our clinic for SARS-CoV-2 related pneumonia. The analysis of patients' smoking history showed that no one was a current smoker, with 112 patients (84.8%) who had never smoked and 20 (15.2%) who were former smokers. These data are in agreement with those from China [3–6]. Furthermore there were no difference in the disease severity between patients who never smoked and former smokers. These data are even more striking if we consider that the percentage of current smokers in Italy and in Veneto Region is 25.7% and 22.7%, respectively [www.epicentro.iss.it/passi/dati/fumo].
Thus, the conclusions of Leung et al. [1] to consider cigarette smoking as a severe risk factor for COVID-19 pneumonia are in contrast with the strong and consolidated epidemiological data coming from China [3–6] that have been confirmed also in our patients.
Footnotes
Conflict of interest: Dr. Rossato has nothing to disclose.
Conflict of interest: Dr. Russo has nothing to disclose.
Conflict of interest: Dr. Mazzocut has nothing to disclose.
Conflict of interest: Dr. Di Vincenzo has nothing to disclose.
Conflict of interest: Dr. Fioretto has nothing to disclose.
Conflict of interest: Dr. Vettor has nothing to disclose.
- Received April 20, 2020.
- Accepted April 21, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.